{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antiviral+Drug+Adverse+Reaction",
    "query": {
      "condition": "Antiviral Drug Adverse Reaction"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T02:12:42.766Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03251144",
      "title": "Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS",
        "Antiviral Toxicity",
        "Antiviral Drug Adverse Reaction",
        "Mitochondrial Alteration"
      ],
      "interventions": [
        {
          "name": "Switch to E/C/FTC/TAF daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2019-04-01",
      "completion_date": "2021-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-05-10",
      "last_synced_at": "2026-05-22T02:12:42.766Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03251144"
    },
    {
      "nct_id": "NCT04340388",
      "title": "Contribution of Dolutegravir to Obesity and Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection",
        "Antiviral Drug Adverse Reaction",
        "Vascular Diseases",
        "Cardiovascular Abnormalities",
        "Abnormality of Adipose Tissue",
        "Body Weight Changes",
        "Body Fat Disorder",
        "HIV-Associated Lipodystrophy Syndrome"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral/Anti HIV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-09-17",
      "completion_date": "2023-02-25",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-05-22T02:12:42.766Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04340388"
    }
  ]
}